TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead...( - Plan Also Calls for Expansion of ...),Health

- Plan Also Calls for Expansion of Business Development, Streamlining of

Operations -

- Company to Host Conference Call/Webcast at 11 a.m. EST Today -

LA JOLLA, Calif., Feb. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced a strategic plan for 2008 with a focus on clinical development activities to maximize the value of the company's versatile lead compounds: AMPA/kainate receptor antagonists tezampanel and NGX426 and muscarinic agonist NGX267. The plan also calls for the expansion of business development initiatives to evaluate partnership opportunities across the company's product pipeline and the streamlining of operations through an expense-reduction program.

Specifically, the company intends to:

Maximize Value of Versatile Lead Compounds

AMPA/kainate receptor antagonists

-- Conduct a Clinical Guidance meeting with the U.S. Food and Drug

Administration (FDA) in the first half of the year to discuss the

efficacy results from the recently completed Phase II clinical

trial of tezampanel in acute migraine headache. As reported last

October, tezampanel met its primary endpoint of headache pain

relief in a double-blind, placebo-controlled, Phase IIb trial in

306 patients with acute migraine. Depending on the outcome of the

meeting, the company intends to conduct an end-of-Phase II meeting

with the FDA in the second half of 2008.

-- Initiate a Phase II trial of tezampanel in muscle spasticity and

rigidity secondary to spinal cord trauma in the second half of the

year. This trial will b
'/>"/>